This week in drug discovery (7-11 February) 

News round-up by DDW’s Megan Thomas for 7-11 February, 2022 

This week has proved eventful in terms of progression in the drug discovery industry. DDW’s Megan Thomas flags five news stories which display this. 

1. Additional dose of Covid-19 vaccine is safe, says US trial 

A study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that an additional dose of a Covid-19 vaccine is safe in adults who had previously received a full regimen of any of three Covid-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA). 

2. Drug discovery collaboration to progress inhibitor project   

Domainex has supported the collaboration between Queen’s University Belfast (UK) and Ipsen to research, develop, manufacture and commercialise FLIP inhibitors – a programme that Domainex has supported since its inception. 

3. Moderna begins Omicron booster trial and presents durability data  

Moderna has dosed the first participant in a Phase II study of the company’s Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralising antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.   

4. Push continues to reduce reliance on animal research methods 

FRAME, a medical research charity that aims to reduce the number of animals used in scientific testing, has awarded a total of £29,000 to three projects with the potential to replace animal use in biomedical research. 

5. New organisation promises smart clinical trials for better health 

Protas, a non-profit organisation which was launched on January 24, will design and deliver large, inclusive, randomised clinical trials, working in collaboration with industry partners, medical charities, patient groups, academic researchers, and frontline clinical teams. Sanofi is its first strategic partner. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free